



MedGenome study analyzing Wellderley data shows interesting trend on gene mutations associated with cardiac function

FOSTER CITY, CA, UNITED STATES, April 12, 2016 /EINPresswire.com/ -- MedGenome will present results from its analysis of the whole genome sequence data from the Wellderly study (Scripps Translational Science Institute) at the



Diabetes Summit 2016, from April 25-27th in Boston, MA.

The study titled "Whole Genome Sequencing data from the Wellderly study identifies rare variants in genes associated with diabetes and cardiomyopathy" involved the analysis of publicly available whole genome sequence data (WGS) of 454 healthy elderly Caucasian individuals (median age 85 years) from the Wellderly study. Genes known to be causative/predictive of diabetes and cardiovascular diseases were analyzed, and results were examined for any rare variants in this population. There were surprisingly few variants of relevance in the diabetic pathway. A significant finding was the discovery of a rare variant of Nebulin (NEB) which was present in about 60% of the individuals in this cohort. Nebulin is a multifunctional protein that binds and stabilizes actin allowing thin filaments to reach mature length. Mutations in NEB are known to be associated with recessive nemaline myopathy but better understanding of its possible protective role in preserving muscle function during aging can provide insights into cardiac conditions that arise due to a loss of muscle function.

About MedGenome

MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Our powerful [genomics solutions](#) accelerate drug discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome is the market leader for [genetic diagnostic testing](#) in India and has worked with thousands of doctors, hospitals, and patients across India by applying Next Generation Sequencing (NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers. For more information, visit us at www.medgenome.com

Forward-looking Statements:

This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of

the date of this press release. The events and circumstances reflected in MedGenome's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Hiranjith GH
MedGenome
7022020883
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.